
About the Program
Program Overview
The ARV Therapies and Therapeutic Strategies program is a comprehensive, independent review of the 22nd International AIDS Conference (AIDS 2018). This program consists of four components: (1) CME Internet Symposium: AIDS 2018 Expert Review: a 1.5 hour Internet symposium that features an overview and discussion of key presentations and posters, selected by the expert faculty discussants; (2) European Perspective on AIDS 2018: a 1 hour panel discussion featuring Europe-based expert faculty reviewing and discussing key presentations with a focus on clinical management and treatment in the EU; (3) Rapid-Fire Review of AIDS 2018: a podcast that provides a brief, audio summary of the most essential data presented at the conference; and (4) From Conference to Clinic: Reviewing and Applying Data From AIDS 2018: case-based dinner meetings during which the key data are reviewed, discussed and applied to patient care.
The European Perspective on AIDS 2018 will provide a case-based, European focused review and discussion of key presentations on antiretroviral therapy presented at EACS 2017. The review and discussion will focus on HIV therapeutic options and developments, including: current treatment and management strategies, algorithms and recommendations, therapies in development, epidemiology, and diagnosis and clinical management of specific patient populations. This activity will enable EU-based health care providers caring for HIV-infected patients to become aware of and understand the data presented at this important conference and appropriately utilize those data to improve patient care in the EU. All online components of the program can be accessed at www.viraled.com.
This program is produced by the Postgraduate Institute for Medicine and ViralEd, Inc. It is not a session created by or presented at AIDS 2018 and it is not sanctioned by the organizers of AIDS 2018.
Target Audience
This activity has been designed to meet the educational needs of physicians, physician assistants, advanced practice nurses and other health care professionals involved in the care of patients with HIV infection.
Learning Objectives
After completing this activity, participants should be better able to:
- Use data reported at AIDS 2018 for counseling, testing and antiretroviral treatment to prevent HIV infection in the EU
- Apply the findings from key studies on HIV/AIDS diagnosis, management, and treatment presented at AIDS 2018
- Employ strategies based on studies and data presented at AIDS 2018 for helping HIV-positive patients in the EU link to and stay in appropriate and effective HIV care
- Describe data and studies regarding the screening, evaluation, management, and treatment of HCV in HIV/HCV co-infected patients presented at AIDS 2018 and use that information to educate, diagnose, manage, and treat HIV/HCV co-infected patients and those HIV patients at risk for HCV
Release Date: August 3, 2018
Expiration Date: August 3, 2019
Estimated time to complete the program: 1 hour, 15 minutes
Faculty
José Arribas, MD
Senior Attending Physician, HIV Unit
Hospital de La Paz
Madrid, Spain
Marta Boffito, MD, PhD
St. Stephen’s AIDS Trust and Imperial College
Chelsea and Westminster Hospital
London, United Kingdom
Franco Maggiolo, MD
Head, Infectious Diseases Department
Papa Giovanni XXIII Hospital
Bergamo, Italy
Graeme Moyle, MD, MB, BS
Associate Director of HIV Research
Chelsea & Westminster Hospital
London, United Kingdom
Jürgen Rockstroh, MD
Professor of Medicine
Department of Medicine
University Hospital
Bonn, Germany
European Continuous Medical Education Credit
AMA PRA Category 1 Credits™ claimed by physicians attending live events certified and organized in the United States for AMA PRA Category 1 Credits™ can be claimed through the agreement on mutual recognition of credits between UEMS and AMA, considered as being equal to the European Continuous Medical Education Credits (ECMEC®) granted by the UEMS. One AMA PRA Category 1 Credit™ is equivalent to one (1) hour of European EACCME Credit (ECMEC®), therefore up to 1.0 ECMEC® Credits are available.
Joint Accreditation Statement
 |
In
support of improving patient care, this activity has been planned and
implemented by the Postgraduate Institute for Medicine and ViralEd, Inc.
Postgraduate Institute for Medicine is jointly accredited by the Accreditation
Council for Continuing Medical Education (ACCME), the Accreditation Council for
Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC),
to provide continuing education for the healthcare team.
|
For Complete Program
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
For Individual Modules
The Postgraduate Institute for Medicine designates each enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
|
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors,
planners, managers and other individuals who are in a position to
control the content of this activity to disclose any real or apparent
conflict of interest (COI) they may have as related to the content of
this activity. All identified COI are thoroughly vetted and resolved
according to PIM policy. PIM is committed to providing its learners
with high quality CME activities and related materials that promote
improvements or quality in healthcare and not a specific proprietary
business interest of a commercial interest.
The faculty reported the following financial
relationships or relationships to products or devices they or their
spouse/life partner have with commercial interests related to the
content of these CME activities:
Jose Arribas, MD
- Consulting Fees: Merck, Gilead, ViiV, Gilead, Janssen
Marta Boffito, MD
- Consulting Fees: Gilead, BMS, ViiV
- Fees for Non-CME/CE Services Received Directly from a Commercial Interest or thier agents (eg. speakers' bureaus): Gilead, Janssen, ViiV, BMS
- Contracted Research: Gilead, Janssen, ViiV, BMS
Graeme Moyle, MD
- Consulting Fees: Gilead, Merck, Janssen
- Contracted Research: ViiV, Gilead, Amgen (to institution)
Juergen Rockstroh, MD
- Consulting Fees: Abbott, Abbivax, Gilead, Hexal, Janssen, Merck, ViiV
- Contracted Research: Gilead, Merck
Franco Maggiolo, MD
- Consulting Fees: BI, BMS, Gilead, GSK, Tibotec
- Fees for Non-CME/CE Services Received Directly from a Commercial Interest or thier agents (eg. speakers' bureaus): BMS, Gilead, GSK, Merck Sharp and Dome
- Contracted Research: BI, BMS, GSK, Janssen-Cilag and Roche
Renslow Sherer, MD
The PIM planners and managers, Trace Hutchison,
PharmD; Samantha Mattiucci, PharmD, CHCP; Judi Smelker-Mitchek, RN, BSN and Jan Shultz, RN, MSN, CHCP
have nothing to disclose.
Method of Participation and Request for Credit
There are no fees for participating and receiving CME/CE credit for this activity. During the period, August 3, 2018 through August 3, 2019, participants must read the learning objectives and faculty disclosures and study the educational activity.
If
you wish to receive acknowledgment for completing this activity, please
complete the evaluation on http://www.cmeuniversity.com/. On the navigation menu, click on "Find Post-test/Evaluation by Course" and search by course ID 13398. Upon registering and successfully completing the activity evaluation, your certificate
will be made available immediately.
Disclosure of Unlabeled Use
This
educational activity may contain discussion of published and/or investigational
uses of agents that are not indicated by the FDA. The planners of this activity
do not recommend the use of any agent outside of the labeled indications.
The
opinions expressed in the educational activity are those of the faculty and do
not necessarily represent the views of the planners. Please refer to the
official prescribing information for each product for discussion of approved
indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired
information to enhance patient outcomes and their own professional
development. The information presented in this activity is not meant to
serve as a guideline for patient management. Any procedures,
medications, or other courses of diagnosis or treatment discussed or
suggested in this activity should not be used by clinicians without
evaluation of their patient's conditions and possible contraindications
on dangers in use, review of any applicable manufacturer's product
information, and comparison with recommendations of other authorities.
Computer System Requirements
This
program requires a modern web browser (Internet Explorer 7+, Mozilla
Firefox, Apple Safari, Google Chrome). Certain educational activities
may require additional software to view multimedia, presentation, or
printable version of their content. These activities will be marked as
such and will provide links to the required software. That software may
be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint,
Windows Media Player and Real Networks Real One Player.
This activity is supported by an independent educational grant from Gilead Sciences Medical Affairs.
This coverage is not sanctioned by the conference organizers and is not an official part of the conference proceedings.
|